SciSparc Ltd.
Business
SciSparc Ltd. is a specialty clinical-stage pharmaceutical company developing cannabinoid-based therapies. It offers proprietary drug candidates (SCI-110 and SCI-210) that combine THC or CBD with CannAmide™ (PEA), a PEA oral tablet product (CannAmide™), and hemp-based nutraceuticals. Key business segments include pharmaceutical drug development and clinical programs for indications such as Tourette syndrome, Alzheimer’s disease agitation, ASD and status epilepticus, a nutraceutical e-commerce division (SciSparc Nutraceuticals), and licensing/collaboration activities. The company conducts clinical trials and seeks regulatory approvals across the U.S., Europe and Israel while marketing nutraceuticals via online channels including Amazon Marketplace.
Summary from filing dated 2025-04-24
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-12.56M |
| Total assets | $7.62M |
| Total liabilities | $2.48M |
| Stockholders' equity | — |
| Operating cash flow | — |